Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (778)	8/6/2001 9:46:10 AM
From: nigel bates	Respond to of 1784

Biacore Launches New High Performance Analytical System UPPSALA, Sweden, Aug. 6 /PRNewswire/ -- Biacore International AB (Biacore) (Nasdaq: BCOR; SSE: BCOR) today announced the launch of its Biacore® S51 system for lead characterization and preclinical applications in drug discovery. This is the first system to be developed from Biacore's new Series S technology platform and is designed to address major analytical problems facing the pharmaceutical industry. Specifically, the system is expected to reduce critical bottlenecks in drug discovery at stages downstream of high-throughput screening (HTS), by providing more biological information on compound activity in a single assay than any technology available today. As the pharmaceutical industry comes under increasing pressure to develop drugs faster and more efficiently, one of the crucial rate-limiting steps is the conversion of HTS 'hits' into lead compounds for preclinical evaluation. Biacore S51 is specifically designed to rapidly and efficiently address key steps in the 'hit'-to-lead selection process, by combining the advantage of Biacore's non-label Surface Plasmon Resonance (SPR) technology with advanced instrumentation and software for higher throughput, enhanced data quality and reduced sample usage. The high quality, quantitative data produced offers unparalleled insight into the binding kinetics, affinity, concentration and specificity of the interaction between a compound and target molecule. Specifically, Biacore S51 provides data-rich analysis in four pivotal stages of the drug discovery and development process: * Rapid confirmation of HTS 'hits' * Comprehensive kinetic characterization of potential lead compounds * Rapid in vitro early ADME (absorption, distribution, metabolism and excretion) analysis to maximize lead selection criteria and define likely in vivo behavior * Detailed kinetics based QSAR (quantitative structure activity relationship) to drive lead optimization Biacore's SPR technology is unique in providing real-time kinetic data from assay formats that require no tags or labeling of compounds, enabling interactions to be studied in near-native states. This offers an unrivalled view of true functionality. Developed in collaboration with companies including Millennium Pharmaceuticals Inc, SmithKline Beecham and Pharmacia Corp, Biacore S51 represents the most advanced commercially available SPR-based instrument. Launched in conjunction with Biacore S51 is a new customer support and assay development program called TecEdge(TM). This unique package provides unparalleled access to Biacore's worldwide team of application and research scientists providing the highest levels of support to users. Application scientists from Biacore are available to work directly with customers in their laboratories to help and guide in the development and design of assay methodology, again with the aim of accelerating the secondary screening applications process. ``Biacore S51 represents a major advance in analytical instrumentation for drug discovery and development in terms of both the quality and quantity of information obtained from a single assay,'' said Julian Abery, VP and Head of the Pharmaceutical and Biotechnology Business Unit at Biacore. ``Biacore is dedicated to providing new and enabling technologies to the drug discovery and development market, and we believe Biacore S51 will be well received. We continue to develop advanced instrumentation to remove bottlenecks at critical stages of lead candidate compound verification. At the same time, we believe our new TecEdge program will facilitate a unique relationship between Biacore and drug development research scientists focused on providing detailed information and identifying new opportunities.''...